Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs iShares MSCI Canada (TSX) (EWC) Price & Performance

Bristol-Myers Squibb CoTrade
iShares MSCI Canada (TSX)Trade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs iShares MSCI Canada (TSX) — how do they compare? Bristol-Myers Squibb Co trades at $63.85 (market cap $129.94B), while iShares MSCI Canada (TSX) trades at $61.68. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares MSCI Canada (TSX) pays none. Which is the better fit depends on your goals.

BMYEWC
Market Cap
$129.94B
Sector
HealthBroad Market / Factor
52-Week High
$65.89$61.51
52-Week Low
$42.60$47.00
Enterprise Value
$163.92B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.

The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.

iShares MSCI Canada (TSX)

EWC trades at $61.81, up 0.5% on the day, with a bullish technical signal driven by moving averages but caution from overbought RSI levels. The ETF shows strong performance in 2026 with double-digit returns, though it trails the S&P 500. Recent news highlights trade tensions with the U.S., including potential 50% tariffs on Canadian goods, but key exclusions may limit material impact.

Outlook remains cautiously optimistic due to Canada's economic resilience and active ETF market growth. Risks include trade war escalation and commodity price volatility, but analyst sentiment supports bullish positioning for diversified exposure to Canadian equities.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About iShares MSCI Canada (TSX)

EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.

Read more on EWC